REGISTER
BeiGene’s Sonrotoclax Approved for Two Indications
Sonrotoclax, a next-generation BCL-2 inhibitor developed by BeiGene, has been approved in China for previously treated CLL/SLL and for mantle cell lymphoma after anti-CD20 and BTK inhibitor therapy. Data presented in 2025 showed rapid and deep responses with a manageable safety profile.

On January 5, the NMPA website showed that BeiGene’s sonrotoclax tablets were approved in China for two indications: 1) treatment of adult patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); and 2) treatment of adult patients with mantle cell lymphoma (MCL) previously treated with anti-CD20 therapy and a BTK inhibitor.

Sonrotoclax is a next-generation BCL-2 inhibitor developed by BeiGene. It is designed to block the BCL-2 protein that helps tumor cells survive. Laboratory and early drug-development studies suggest that sonrotoclax is a potent and selective BCL-2 inhibitor with a short half-life and no accumulation.

CLL is a life-threatening adult cancer arising from abnormal leukemic B lymphocytes in the bone marrow that accumulate in peripheral blood, bone marrow, and lymphoid tissues, forming a mature B-cell malignancy. SLL is another manifestation of the same disease, and about 20% of SLL cases progress to CLL.

Compared with Western countries, Chinese patients with CLL/SLL have a shorter median survival and are more likely to experience disease progression and relapse, resulting in poorer overall prognosis. With population aging and increasingly precise clinical diagnosis in China, the incidence of CLL/SLL continues to rise and unmet need remains substantial.

At the 2025 American Society of Hematology (ASH) Annual Meeting, BeiGene reported efficacy and safety data from an open-label Phase II study (BGB-11417-202) of sonrotoclax in patients with relapsed/refractory CLL/SLL who had received extensive prior treatment.

In patients with relapsed/refractory CLL/SLL, monotherapy with sonrotoclax achieved an ORR of 76% by independent review committee (IRC) assessment, with a complete response/complete response with incomplete marrow recovery (CR/CRi) rate of 19%, showing rapid and deep responses. With a median follow-up of 14.4 months, the primary analysis showed that patients with unmutated IGHV, 17p deletion and/or TP53 mutation, and BTK mutations had similar ORR and CR outcomes. Median time to response was 3.7 months. The best peripheral blood undetectable minimal residual disease rate was 49.0%, and the median time to achieve peripheral blood uMRD4 was 5.8 months. Sonrotoclax monotherapy was well tolerated, with manageable toxicity and no clinical tumor lysis syndrome.

MCL is a life-threatening B-cell lymphoma characterized by the rapid progression of aggressive lymphoma and the incurability of indolent lymphoma. The incidence of MCL in China is approximately 0.62 per 100,000, is slightly higher in men, and has a median onset age of around 60 years. As the population ages, the incidence of MCL is rising in China.

In August 2025, BeiGene announced positive results from a global, multicenter, single-arm, open-label Phase I/II study (BGB-11417-201) of sonrotoclax in adult patients with MCL previously treated with a BTK inhibitor and anti-CD20 therapy.

At the 2025 ASH Annual Meeting, BeiGene presented the full data. In the study, relapsed/refractory MCL patients previously treated with anti-CD20 therapy and a BTK inhibitor (n=103) received 320 mg sonrotoclax; IRC-assessed ORR was 52.4%, with a complete response rate of 15.5%. Notably, benefit was consistent in high-risk disease subtypes, including patients with TP53 mutation, an important prognostic marker in MCL; in this subgroup, IRC-assessed ORR was 59.1%.

With a median follow-up of 14.2 months, median duration of response by IRC was 15.8 months and data were not yet fully mature. Median time to response was 1.9 months and median PFS was 6.5 months. Sonrotoclax monotherapy was generally well tolerated and adverse events were manageable. The most common grade 3 or higher treatment-emergent adverse events occurring in more than 10% of patients were neutropenia, infections, and infectious pneumonia.

Notably, based on these positive results, the FDA accepted a new drug application for sonrotoclax in November 2025 and granted priority review for the treatment of relapsed/refractory MCL after BTK inhibitor therapy.

According to the Insight database, only AbbVie’s venetoclax and Ascentage Pharma’s lisaftoclax have so far been approved globally in the BCL-2 field. With this approval, BeiGene’s sonrotoclax becomes the third approved BCL-2 inhibitor worldwide and the second developed in China.

0
0
Loading